PVR and non-small cell lung carcinoma: Despite these findings, there is limited clinical evidence regarding the prognostic role of CD155 in individuals with NSCLC harboring the most common oncogenic alterations, such as Epidermal Growth Factor Receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations.